Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Paul Baas

Showing results (11-20 of 193) with videos related to

Pageof 20
Sort By:
The Lancet. Respiratory Medicine|May 19, 2018
Immuno-oncology in malignant pleural mesotheliomaPaul Baas, Maria Disselhorst
Respirology (Carlton, Vic.)|April 2, 2015
ASIA: asbestos stop in AsiaPaul Baas, Sjaak Burgers
The Annals of Thoracic Surgery|June 30, 2004
Foscan-mediated photodynamic therapy and operation for malignant pleural mesotheliomaHugo Schouwink, Paul Baas
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2024
Immunotherapy Is a Good Standard Option for Patients With Malignant Pleural Mesothelioma, Despite the Real-World Results From AustraliaIllaa Smesseim, Paul Baas
Translational Lung Cancer Research|February 10, 2023
The path forward in early-stage lung cancerKristof Cuppens, Paul Baas
Nature Reviews. Clinical Oncology|January 1, 2016
Lung cancer in 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targetsEgbert F Smit, Paul Baas
Lung Cancer (Amsterdam, Netherlands)|November 28, 2015
Money rules the worldPaul Baas, Jan van Meerbeeck
Translational Lung Cancer Research|March 25, 2020
Chemotherapy options versus "novel" therapies: how should we treat patients with malignant pleural mesotheliomaMaria J Disselhorst, Paul Baas
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|November 6, 2002
Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLCNico Van Zandwijk, Paul Baas
European Journal of Cancer (Oxford, England : 1990)|June 16, 2009
Palliative chemotherapy: do we need yet another end-point?Jan P van Meerbeeck, Paul Baas
Pageof 20

Showing results (11-20 of 193) with videos related to

Sort By:
Pageof 20
The Lancet. Respiratory Medicine|May 19, 2018
Immuno-oncology in malignant pleural mesotheliomaPaul Baas, Maria Disselhorst
Respirology (Carlton, Vic.)|April 2, 2015
ASIA: asbestos stop in AsiaPaul Baas, Sjaak Burgers
The Annals of Thoracic Surgery|June 30, 2004
Foscan-mediated photodynamic therapy and operation for malignant pleural mesotheliomaHugo Schouwink, Paul Baas
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|April 6, 2024
Immunotherapy Is a Good Standard Option for Patients With Malignant Pleural Mesothelioma, Despite the Real-World Results From AustraliaIllaa Smesseim, Paul Baas
Translational Lung Cancer Research|February 10, 2023
The path forward in early-stage lung cancerKristof Cuppens, Paul Baas
Nature Reviews. Clinical Oncology|January 1, 2016
Lung cancer in 2015: Bypassing checkpoints, overcoming resistance, and honing in on new targetsEgbert F Smit, Paul Baas
Lung Cancer (Amsterdam, Netherlands)|November 28, 2015
Money rules the worldPaul Baas, Jan van Meerbeeck
Translational Lung Cancer Research|March 25, 2020
Chemotherapy options versus "novel" therapies: how should we treat patients with malignant pleural mesotheliomaMaria J Disselhorst, Paul Baas
I Supplementi Di Tumori : Official Journal of Societa Italiana Di Cancerologia ... [Et Al.]|November 6, 2002
Second/third/fourth line therapy with tyrosine kinase inhibitors in NSCLCNico Van Zandwijk, Paul Baas
European Journal of Cancer (Oxford, England : 1990)|June 16, 2009
Palliative chemotherapy: do we need yet another end-point?Jan P van Meerbeeck, Paul Baas
Pageof 20